ePrescribing: What Role Should Pharma Play?

A panel entitled What Role Should Pharma Play in ePrescribing and the Point-of-Care? at a recent ePharma Summit conference held in Philadelphia, PA, discussed the issues facing pharmaceutical companies as electronic prescribing (ePrescribing or eRx) threatens to upset the "balance of power" between physicians, pharma companies, and payers at the point-of-care.

Pharma eMarketing: A Level Playing Field or a Killing Field?

Why is pharma so conservative when it comes to using technology for marketing purposes? Is it ROI concerns? Not invented here syndrome? Or is it something else?

Physician Adoption and Use of Technology at the Point of Care

This article provides insight from experts such as Mark Bard, President of Manhattan Research and David Kibbe, M.D., Director, Healthcare Information Technology, American Academy of Family Physicians (AAFP), on the impact of new technologies at the point of care on pharmaceutical sales and marketing.

Commercial Support of CME: When is it Appropriate?

On April 1, 2004, the Board of Directors of the Accreditation Council for Continuing Medical Education (ACCME), by unanimous vote, adopted the updated ACCME Standards for Commercial Support of Continuing Medical Education. This article summarizes when it is and is not appropriate for pharmaceutical companies to support independent CME programs.

The Truth About the Drug Companies: What To Do About It

You can't go to a pharma industry conference these days without hearing at least one expert speaker recommending that pharma executives read the book 'The Truth About the Drug Companies: How They Deceive Us and What to do About It,' written by Marcia Angell, MD, former editor in chief of The New England Journal of Medicine. This review includes several point-counter point views regarding Angell's arguments by pharmaceutical and healthcare experts, including members of the PHARMA-MKTING online discussion group.

Effective Pharma Adherence Programs Start With The Patient

Patient compliance may be a core objective for pharma marketers, but an international quorum of compliance experts at the recent eyeforpharma Patient Compliance 2004 conference in London agreed that the very term 'compliance is incorrect. In 22 in-depth presentations over 2 days, 30 speakers and panelists agreed that marketers need to stop analyzing compliance, and start understanding patients.

OpEd: Is DTC Educational or Motivational?

What is the proper role of DTCA - educational or motivational? Is it capable of doing either? If so, how well is it doing?

OpEd: Corporate “Moral Values” Anyone?

A few days after Merck pulled Vioxx from the market it was revealed that the drug manufacturer may have known about Vioxx's cardiovascular side effect problems for years and tried very hard to conceal the evidence and block any action by the FDA. While this was going on an estimated 27,000 people suffered heart attacks and who knows how many strokes possibly due to Vioxx! hard to conceal the evidence and block any action by the FDA. While this was going on an estimated 27,000 people suffered heart attacks and who knows how many strokes possibly due to Vioxx! If this obstructionism by Merck is true, then someone should pay.

European Compliance Not Only Possible, But Leading Edge

As US pharmaceutical companies search for best practices to battle patient drop-off, their European counterparts have overcome Byzantine regulations and reduced margins to implement strikingly effective compliance programs.

The New Written Prescription: Leveraging Technology to Measure Change in Physician Behavior as it...

New Written Prescriptions (NWRx's), which are uncontaminated by managed care intervention and patient fulfillment issues, are the ultimate measure of physician behavior and, therefore, the purest measure of promotional effectiveness, according to Nancy S. Lurker, CEO of ImpactRx. This article highlights real world examples of the differences between analyses performed using ImpactRx's NWRx's for patients new to or switching therapy versus those using traditional dispensed new prescription data.
- Advertisement -